Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Gross Margin came in at 91.63% in Q1 2026, up 535.0% YoY from 14.43% in Q1 2025, and up 3.43% on a QoQ basis from 88.59% in Q4 2025.
Powered by 
Analysis
Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 7 years of Gross Margin data on file, last reported at 91.63% in Q1 2026.
- Quarterly Gross Margin rose 535.0% year-over-year to 91.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.74% (up 150.0% YoY) and the FY2025 annual result came in at 88.46%, up 47.0% from the prior year.
- Gross Margin climbed to 91.63% in Q1 2026, from 88.59% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 98.82% in Q1 2022 to a low of 84.42% in Q2 2024.
- A 5-year average of 91.21% and a median of 90.73% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin slumped 1419 bps — and 2025, when it jumped 541 bps.
- Tracing AUPH's Gross Margin over 5 years: stood at 95.21% in 2022, then declined by 8 bps to 88.04% in 2023, then rose by 3 bps to 90.73% in 2024, then decreased by 2 bps to 88.59% in 2025, then rose by 3 bps to 91.63% in 2026.
- The last three Gross Margin figures came in at 91.63% (Q1 2026), 88.59% (Q4 2025), and 88.87% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Aurinia Pharmaceuticals | 2.10 Bn | 1.66 Bn | 76.67 Mn | 92.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.12% |
| Mar 31, 2026 | 91.63% |
| Dec 31, 2025 | 88.59% |
| Sep 30, 2025 | 88.87% |
| Jun 30, 2025 | 89.84% |
| Mar 31, 2025 | 86.27% |
| Dec 31, 2024 | 90.73% |
| Sep 30, 2024 | 91.10% |
| Jun 30, 2024 | 84.42% |
| Mar 31, 2024 | 84.59% |
| Dec 31, 2023 | 88.04% |
| Sep 30, 2023 | 87.58% |
| Jun 30, 2023 | 96.23% |
| Mar 31, 2023 | 98.78% |
| Dec 31, 2022 | 95.21% |
| Sep 30, 2022 | 95.61% |
| Jun 30, 2022 | 94.33% |
| Mar 31, 2022 | 98.82% |
| Dec 31, 2021 | 97.94% |
| Sep 30, 2021 | 98.27% |